๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Pelabresib

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 5 trials in our UK, USA, China and India registers that name Pelabresib as an intervention. Synced 24 Sep 2026
5Trials tracked
4Recruiting now
1Lead sponsor
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Pelabresib is named as a drug or biological intervention in 5 clinical trials in our UK, USA, China and India trial registers, 4 of which are recruiting. The lead sponsor is Novartis Pharmaceuticals. Registered phases: Phase 3 and Phase 1. Conditions studied include Advanced Malignancies and Hepatic Impairment; Hematologic Malignancy; Solid Tumor.

01

Clinical trials of Pelabresib

5 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06401356 An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Phase 3 Recruiting Novartis Pharmaceuticals UK, USA
NCT07357727 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (ClinicalTrials.gov ↗)
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Phase 3 Recruiting Novartis Pharmaceuticals USA, India, China
NCT07422610 Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Advanced Malignancies and Hepatic Impairment
Phase 1 Recruiting Novartis Pharmaceuticals UK
NCT07783503 A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants (ClinicalTrials.gov ↗)
Healthy Participants
Phase 1 Recruiting Novartis Pharmaceuticals UK
NCT04603495 Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (ClinicalTrials.gov ↗)
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 3 Active, closed Novartis Pharmaceuticals UK, USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

12 conditions
Condition (as registered)Trials
Advanced Malignancies and Hepatic Impairment1
Hematologic Malignancy1
Solid Tumor1
Advanced Malignancies1
Healthy Participants1
Myelofibrosis1
Primary Myelofibrosis1
Post-polycythemia Vera Myelofibrosis1
Post-essential Thrombocythemia Myelofibrosis1
Primary Myelofibrosis (PMF)1
Post-polycythemia Vera Myelofibrosis (PPV-MF)1
Post-essential Thrombocythemia Myelofibrosis (PET-MF)1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Novartis Pharmaceuticals5
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Pelabresib works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pelabresib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.